Q1 2024 Earnings Estimate for EyePoint Pharmaceuticals, Inc. Issued By Capital One Financial (NASDAQ:EYPT)

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Equities research analysts at Capital One Financial lifted their Q1 2024 earnings estimates for shares of EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, May 6th. Capital One Financial analyst T. Chiang now anticipates that the company will post earnings per share of ($0.32) for the quarter, up from their prior forecast of ($0.39). Capital One Financial has a “Overweight” rating on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($1.73) per share. Capital One Financial also issued estimates for EyePoint Pharmaceuticals’ Q2 2024 earnings at ($0.38) EPS, Q3 2024 earnings at ($0.45) EPS, Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.62) EPS, FY2025 earnings at ($2.03) EPS, FY2026 earnings at ($2.63) EPS, FY2027 earnings at ($0.44) EPS and FY2028 earnings at $3.36 EPS.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.27. EyePoint Pharmaceuticals had a negative net margin of 153.84% and a negative return on equity of 61.48%. The business had revenue of $14.03 million during the quarter, compared to the consensus estimate of $8.71 million. During the same quarter in the prior year, the firm earned ($0.61) EPS.

EYPT has been the subject of a number of other reports. Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $39.00 to $28.00 and set a “buy” rating for the company in a research report on Tuesday. Mizuho decreased their price target on EyePoint Pharmaceuticals from $39.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. JPMorgan Chase & Co. assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Monday, January 22nd. They set an “overweight” rating and a $35.00 price objective for the company. Robert W. Baird reduced their target price on shares of EyePoint Pharmaceuticals from $46.00 to $38.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, HC Wainwright dropped their price target on shares of EyePoint Pharmaceuticals from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, January 16th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.14.

EyePoint Pharmaceuticals Trading Down 2.6 %

Shares of EyePoint Pharmaceuticals stock opened at $11.56 on Thursday. EyePoint Pharmaceuticals has a 12 month low of $5.67 and a 12 month high of $30.99. The stock has a 50 day moving average of $20.64 and a 200 day moving average of $19.14. The firm has a market cap of $602.09 million, a PE ratio of -6.32 and a beta of 1.70.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Federated Hermes Inc. grew its position in shares of EyePoint Pharmaceuticals by 194.0% during the 4th quarter. Federated Hermes Inc. now owns 674,824 shares of the company’s stock worth $15,595,000 after buying an additional 445,289 shares in the last quarter. Jennison Associates LLC purchased a new position in EyePoint Pharmaceuticals during the 4th quarter valued at about $24,641,000. Barclays PLC raised its holdings in shares of EyePoint Pharmaceuticals by 103.4% in the 3rd quarter. Barclays PLC now owns 45,659 shares of the company’s stock valued at $365,000 after purchasing an additional 23,208 shares in the last quarter. TD Asset Management Inc purchased a new stake in shares of EyePoint Pharmaceuticals in the 3rd quarter worth approximately $574,000. Finally, DekaBank Deutsche Girozentrale bought a new position in shares of EyePoint Pharmaceuticals during the fourth quarter valued at approximately $820,000. Institutional investors own 99.41% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Cormorant Asset Management, Lp bought 850,000 shares of the company’s stock in a transaction on Monday, May 6th. The shares were acquired at an average cost of $11.86 per share, for a total transaction of $10,081,000.00. Following the purchase, the insider now directly owns 8,325,000 shares of the company’s stock, valued at $98,734,500. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 13.05% of the stock is currently owned by insiders.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.